ArticleBMC nephrology2025
Occurrence of benzodiazepines and nonbenzodiazepines usage among newly-onset of peritoneal dialysis versus hemodialysis patients.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe use of central nervous system depressants, including benzodiazepines (BZDs) and nonbenzodiazepine hypnotics (Z-drugs), is increasingly observed in chronic dialysis patients. Hemodialysis (HD) and peritoneal dialysis (PD) patients differ in physiological stress and neuropsychiatric profiles, yet both groups are exposed to medications such as BZDs and Z-drugs, whose adverse effects including sedation, cognitive impairment, and increased mortality, may further compound the psychological vulnerability and survival risks inherent to these dialysis populations. However, comparative patterns of their use across dialysis modalities remain insufficiently understood.
methodsIn this retrospective study, we enrolled patients newly diagnosed with end-stage renal disease who met the criteria for catastrophic illness in the National Health Insurance Research Database (NHIRD) between January 1, 2007, and December 31, 2017. PD and HD patients were propensity score–matched in a 1:3 ratio. Kaplan–Meier methods were used to estimate the new-onset BZDs and Z-drugs usage rate and to construct survival curves. Cox proportional hazards regression models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for new-onset BZDs and Z-drugs use between PD and HD groups. Follow-up ended no later than December 31, 2020.
resultsThe study compares BZDs and Z-drugs usage between PD and HD patients across three different time intervals: within 90 days, within 270 days, and after 270 days. Initially, PD patients had a significantly lower incidence of BZDs usage [aHR 0.858 (95% CI 0.740–0.993)]. However, this advantage diminished over time and reversed after 270 days, while PD patients showing higher rates of BZDs usage [aHR 1.446 (95% CI 1.286–1.627)]. In contrast, Z-drugs usage rate showed no statistically significant difference between the two groups across all intervals.
conclusionsWhen compared to patients on HD, those on PD exhibit a gradual rise in BZDs usage over time, which raises concerns about concurrent psychological symptoms. Further research is required to explore the neuropsychological mechanisms underlying psychological problems in patients on long-term PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.